Browsing Centre for Immunobiology by Author "Baeten, J"
Now showing items 1-3 of 3
-
5-year outcomes of bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 cell count in two Phase 3 randomised clinical trials
Ramgopal, M; Warupa, A; Baumgarten, A; Berhe, M; Pozniak, A; Orkin, C; Tiraboschi, JM; Hagins, D; Huang, H; Andreatta, K (2023) -
Long-term integrated analysis of B/F/TAF in treatment-naive adults with HIV through five years of follow-up
Sax, P; Arribas, J; Orkin, C; Lazzarin, A; Pozniak, A; Maggiolo, F; Stellbrink, H-J; Yazdanpanah, Y; Acosta, R; Huang, H (2023) -
Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
Orkin, C; Antinori, A; Rockstroh, J; Guillen, SM; Martorell, C; Molina, J-M; Lazzarin, A; Maggiolo, F; Yazdanpanah, Y; Andreatta, K (2023)